TABLE 3.

Average per year OOP expenditures for male cancer survivors^a

	Current cancer condition		No current cancer condition
Cancer status and type	Average out-of-pocket expenditures, $USb	P c	Average out-of-pocket expenditures, $USb	P c
No history of cancer [Reference]	621		621
Prostate cancer	1,457	<0.001	1,152	0.002
Lung cancer	1,131	0.027	1,323d	0.031
Colon cancer	1,471	0.001	966	0.028
Melanoma	1,474	<0.001	1,351	0.001
Non–Hodgkin lymphoma	1,653	0.005	646	0.916
Nonmelanoma/other skin cancer	1,789	<0.001	1,478	<0.001
Bladder cancer	2,157	<0.001	1,321	0.019
Other/unspecified	2,255	<0.001	1,080	0.003
≥ Two cancers	2,642	<0.001	1,433	0.009

^aEstimates were obtained from survey weighted and covariate adjusted analysis of pooled Medical Expenditure Panel Survey data for the years 2009–2015 and 2018. The dollar values were inflation-adjusted to 2018 U.S. dollars using the consumer price index (CPI).

^bEstimated average OOP expenditure by applying the two-part regression model to specific cancer subtypes. Each model was adjusted for age, cancer status and types, race/ethnicity, marital status, educational attainment, income level, insurance status, survey year, number of comorbid conditions, and self-reported health status.

^c P value represents the statistical significance obtained using 1,000 permutated replicates to test the hypothesis that the estimated average OOP expenditure for each cancer category is different than “no history of cancer” category (two-sided P-value). Each replicate model was adjusted for the same set of predictors as the base model, and the dependent variable, OOP expenditure, was permuted for each replicate analysis.

^dUnweighted sample size less than 60.